Stocks Higher as In...
Health Care: Drugs
AcelRx Pharmaceuticals Inc. (ACRX: NASDAQ)
$9.60 -0.32 | -3.23%
06/18/13 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 18.60 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 18.70 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 8.60 | 12.50 |
| Beta | 1.79 | 0.58 | 0.98 |
| Price to Sales (TTM) | 118.96 | 3.20 | 1.42 |
| Price to Book (MRQ) | 16.31 | 3.92 | 2.41 |
| Price to Tangible Book (MRQ) | 16.31 | 57.35 | 5.08 |
| Price to Cash Flow (TTM) | -6.80 | 12.30 | 9.80 |
| Price to Free Cash Flow (TTM) | -13.30 | 40.90 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 3.40 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 3.90 | 2.30 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 2.79 | 2.61 |
| Payout Ratio (TTM) | 0.00 | 62.00 | 37.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 185.70 | -8.70 | -0.90 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 123.30 | -3.50 | 2.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 2.84 | 3.97 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -0.80 | 18.70 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -0.80 | 18.70 |
| EPS - 5 Yr Growth Rate (%) | n.a. | -1.24 | 8.27 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -10.61 | 4.03 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.20 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 3.40 | 1.70 | 1.60 |
| LT Debt to Equity (MRQ) | 0.30 | 0.38 | 0.73 |
| Total Debt to Equity (MRQ) | 0.65 | 0.49 | 0.86 |
| Interest Coverage (TTM) | n.a. | 13.10 | 6.40 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 76.50 | 47.50 |
| Gross Margin - 5 Yr Avg | n.a. | 77.70 | 46.90 |
| EBITD Margin (TTM) | n.a. | 30.60 | 19.40 |
| EBITD - 5 Yr Avg | 0.00 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 19.70 | 11.30 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 22.10 | 10.10 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.00 | 0.17 | 0.08 |
| Net Profit Margin - 5 Yr Avg | n.a. | 17.40 | 7.00 |
| Return on Assets (TTM) | -100.60 | 9.90 | 3.10 |
| Return on Assets - 5 Yr Avg | n.a. | 8.50 | 2.50 |
| Return on Investment (TTM) | -187.00 | 15.90 | 8.20 |
| Return on Investment - 5 Yr Avg | n.a. | 13.60 | 6.60 |
| Efficiency | |||
| Revenue/Employee (TTM) | 120,200.00 | n.a. | n.a. |
| Net Income/Employee (TTM) | -213,276.00 | n.a. | n.a. |
| Receivable Turnover (TTM) | n.a. | 5.00 | 7.90 |
| Inventory Turnover (TTM) | n.a. | 2.30 | 7.70 |
| Asset Turnover (TTM) | 0.10 | 0.60 | 0.40 |
Portfolios with ACRX
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
Latest ACRX Headlines from TheStreet
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- 5 Stocks Insiders Are Stuffing in Their Stockings 12.12.12 | 12:12 pm
- Dunkin' Brands Prices IPO Above Range 07.26.11 | 07:07 pm
- IPO Lessons From Pandora 02.16.11 | 01:02 pm
- IPO Watch: 2011 02.16.11 | 01:02 pm
- Gaskins Warns on Speculative Pharma IPOs
02.02.11 | 08:02 am
Press Releases for ACRX
- AcelRx Pharmaceuticals To Present At The Jefferies 2013 Global Healthcare - PR Newswire 05.29.13 | 07:05 am
- AcelRx Pharmaceuticals To Present At The UBS Global Healthcare Conference - PR Newswire 05.16.13 | 03:05 pm
- AcelRx Pharmaceuticals To Hold First Quarter 2013 Financial Results Conference Call And Webcast On May 8, 2013 - PR Newswire 05.03.13 | 07:05 am
- AcelRx Pharmaceuticals Presents Positive Clinical Data For The Sufentanil NanoTab PCA System At ASRA Medical Meeting - PR Newswire 05.02.13 | 07:05 am
- Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint In Dose-Finding Phase 2 Clinical Trial - PR Newswire 04.24.13 | 07:04 am
- AcelRx Pharmaceuticals To Hold Fourth Quarter 2012 Financial Results Conference Call And Webcast On March 12, 2013 - PR Newswire 03.07.13 | 07:03 am
- AcelRx Top-line Data Show Primary Endpoint Achieved In Pivotal Phase 3 Study Of Sufentanil NanoTab PCA System For Post-Operative Pain In Major Open Abdominal Surgery Patients - PR Newswire 03.04.13 | 06:03 pm
- AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.27.13 | 07:02 am
- AcelRx Pharmaceuticals Provides Clinical Trial Updates - PR Newswire 02.19.13 | 07:02 am
- AcelRx Appoints Adrian Adams To Board Of Directors As Chairman - PR Newswire 02.12.13 | 07:02 am
Partner Headlines for ACRX
- UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01 - Benzinga 04.08.13 | 09:04 am
- After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP - NASDAQ 03.12.13 | 06:03 pm
- AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts - Seeking Alpha 12.22.12 | 09:12 am
- FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain - Benzinga 11.15.12 | 08:11 am
- New IPO Filings And What's On The Horizon - Seeking Alpha 02.03.12 | 06:02 pm
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
